{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:28:00Z","timestamp":1792798080441,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.phrs.2025.107805","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:37:02Z","timestamp":1748597822000},"page":"107805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update"],"prefix":"10.1016","volume":"217","author":[{"given":"Robert","family":"Roskoski Jr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107805_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107805_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.107805_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2025.107805_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med Chem."},{"issue":"68","key":"10.1016\/j.phrs.2025.107805_bib6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.jmedchem.4c02661","article-title":"A medicinal chemistry perspective on FDA-approved small molecule drugs with a covalent mechanism of action","volume":"13","author":"Dalton","year":"2025","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib7","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107805_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107805_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107805_bib10","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1734-1140(10)70308-X","article-title":"Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology","volume":"62","author":"Botting","year":"2010","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.phrs.2025.107805_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward","year":"2013","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bi00646a018","article-title":"The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase","volume":"15","author":"Maycock","year":"1976","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2025.107805_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107805_bib18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/1097-0142(19830515)51:10<1787::AID-CNCR2820511004>3.0.CO;2-A","article-title":"The epidermal growth factor (EGF)","volume":"51","author":"Cohen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2025.107805_bib19","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0021-9258(19)68224-4","article-title":"A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles","volume":"257","author":"Cohen","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib21","first-page":"88","article-title":"The under-appreciated promiscuity of the epidermal growth factor receptor family","volume":"4","author":"Kennedy","year":"2016","journal-title":"Front Cell Dev. Biol. 2016"},{"key":"10.1016\/j.phrs.2025.107805_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2004.04.150","article-title":"The ErbB\/HER receptor protein-tyrosine kinases and cancer","volume":"319","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2025.107805_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: Structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107805_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107805_bib28","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107805_bib30","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107805_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107805_bib32","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.9.13.7557015","article-title":"How do protein kinases discriminate between serine\/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase","volume":"9","author":"Taylor","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107805_bib33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-291X(92)90812-Y","article-title":"A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor","volume":"186","author":"Gotoh","year":"1992","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2025.107805_bib34","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib35","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib39","first-page":"784","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Re.s"},{"key":"10.1016\/j.phrs.2025.107805_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2025.107805_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib49","series-title":"Reference module in life sciences","first-page":"1","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2025.107805_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2025.107805_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107805_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib58","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib59","first-page":"1219","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorganic","volume":"6","author":"Liu","year":"1998","journal-title":"Med Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib60","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2025.107805_bib61","doi-asserted-by":"crossref","unstructured":"Vetrie D., Vorechovsk\u00fd I., Sideras P., Holland J., Davies A., Flinter F., Hammarstr\u00f6m L., Kinnon C., Levinsky R., Bobrow M., Edvard Smith C.I., Bentley D.R.. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226\u201333. doi: 10.1038\/361226a0. Erratum in: Nature 1993;364:362.","DOI":"10.1038\/361226a0"},{"key":"10.1016\/j.phrs.2025.107805_bib62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107805_bib63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107805_bib64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.8332901","article-title":"Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice","volume":"261","author":"Rawlings","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107805_bib65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.phrs.2025.107805_bib66","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib67","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.molcel.2006.01.022","article-title":"Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction","volume":"21","author":"Furdui","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.107805_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107805_bib69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib70","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2025.107805_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib72","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.107805_bib74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, Version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.phrs.2025.107805_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107465","article-title":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","volume":"209","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib76","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2024.10.006","article-title":"Lung cancer research and treatment: global perspectives and strategic calls to action","volume":"35","author":"Meyer","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib77","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2025.107805_bib78","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2025.107805_bib79","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2025.107805_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib81","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.2147\/CMAR.S235121","article-title":"Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options","volume":"12","author":"Gampenrieder","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.phrs.2025.107805_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14656566.8.4.485","article-title":"Docetaxel\/anthracycline combinations for breast cancer treatment","volume":"8","author":"von Minckwitz","year":"2007","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.phrs.2025.107805_bib83","first-page":"224","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov","volume":"3","author":"Bose","year":"2013"},{"key":"10.1016\/j.phrs.2025.107805_bib84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib86","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107805_bib87","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107805_bib88","article-title":"Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies","author":"Danilov","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2025.107805_bib89","doi-asserted-by":"crossref","unstructured":"Gertz M.A. Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management. Am J Hematol 2025 Mar 17. doi: 10.1002\/ajh.27666.","DOI":"10.1002\/ajh.27666"},{"key":"10.1016\/j.phrs.2025.107805_bib90","doi-asserted-by":"crossref","unstructured":"Castillo J.J., Treon S.P.. Management of Waldenstr\u00f6m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program 2020;2020:3723379. doi: 10.1182\/hematology.2020000121.","DOI":"10.1182\/hematology.2020000121"},{"key":"10.1016\/j.phrs.2025.107805_bib91","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70170","article-title":"Covalent Bruton tyrosine kinase inhibitors across generations: a focus on zanubrutinib","volume":"29","author":"Broccoli","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib92","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-23-1042","article-title":"FDA approval summary: futibatinib for unresectable advanced or metastatic, chemotherapy refractory intrahepatic cholangiocarcinoma with FGFR2 fusions or other rearrangements","volume":"29","author":"Gandhy","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2025.107805_bib93","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tips.2022.12.007","article-title":"Futibatinib (Lytgobi) for cholangiocarcinoma","volume":"44","author":"Roskoski","year":"2023","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jdv.18810","article-title":"Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur","volume":"37","author":"Gupta","year":"2023","journal-title":"Acad. Dermatol. Venereol."},{"key":"10.1016\/j.phrs.2025.107805_bib95","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/13543784.2024.2348062","article-title":"Novel investigational drugs for alopecia areata and future perspectives","volume":"33","author":"Chim","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2025.107805_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/pde.15842","article-title":"Pathophysiology of alopecia areata in the pediatric patient","volume":"42","author":"Fitzhugh","year":"2025","journal-title":"Pedia Dermatol."},{"key":"10.1016\/j.phrs.2025.107805_bib97","article-title":"Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors","author":"Dainichi","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.phrs.2025.107805_bib98","doi-asserted-by":"crossref","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107805_bib99","first-page":"434","article-title":"LITFULO\u2122 (Ritlecitinib) capsules: a Janus kinase 3 inhibitor for the treatment of severe alopecia areata","volume":"21","author":"Gupta","year":"2023","journal-title":"Skinmed 2023"},{"key":"10.1016\/j.phrs.2025.107805_bib100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem."},{"key":"10.1016\/j.phrs.2025.107805_bib101","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2025.107805_bib103","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2025.107805_bib104","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.phrs.2025.107805_bib106","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","volume":"49","author":"Kanev","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2025.107805_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib108","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3747\/co.25.3732","article-title":"Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib109","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib110","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib111","doi-asserted-by":"crossref","unstructured":"Hochmair M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and\/or leptomeningeal disease. Target Oncol 2018;13:269\u201385. doi: 10.1007\/s11523-018-0566-1. Erratum in: Target Oncol 2018;13:667. doi: 10.1007\/s11523-018-0598-6.","DOI":"10.1007\/s11523-018-0566-1"},{"key":"10.1016\/j.phrs.2025.107805_bib112","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.107805_bib113","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2025.107805_bib114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107805_bib115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib116","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107805_bib117","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib118","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.2147\/DDDT.S52787","article-title":"Dacomitinib in lung cancer: a \"lost generation\" EGFR tyrosine-kinase inhibitor from a bygone era?","volume":"9","author":"Ou","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2025.107805_bib119","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtho.2018.01.009","article-title":"EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib","volume":"13","author":"Kobayashi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953013","article-title":"Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020","volume":"12","author":"Kooijman","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib122","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2025.107805_bib123","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib124","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib125","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acsmedchemlett.2c00213","article-title":"Structural basis for inhibition of mutant EGFR with lazertinib (YH25448)","volume":"13","author":"Heppner","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2025.107805_bib126","doi-asserted-by":"crossref","DOI":"10.1039\/D4MD00800F","article-title":"Lazertinib: breaking the mold of third-generation EGFR inhibitors","author":"Patel","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129084","article-title":"Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"80","author":"Huang","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2025.107805_bib128","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"suppl_1","key":"10.1016\/j.phrs.2025.107805_bib129","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib130","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jsb.2015.10.018","article-title":"Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed","volume":"192","author":"Yosaatmadja","year":"2015","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib131","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/jm040159c","article-title":"Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity","volume":"48","author":"Tsou","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib132","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2025.107805_bib133","first-page":"2183","article-title":"Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs","volume":"16","author":"Jiang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2025.107805_bib134","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and Drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107805_bib135","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107805_bib136","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ml300327z","article-title":"Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M\/L858R mutant inhibitors","volume":"4","author":"Sogabe","year":"2012","journal-title":"ACS Med Chem. Lett."},{"key":"10.1016\/j.phrs.2025.107805_bib137","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: First Global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107805_bib139","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107805_bib140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/fon-2018-0637","article-title":"Acalabrutinib and its use in treatment of chronic lymphocytic leukemia","volume":"15","author":"Khan","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib141","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib142","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2025.107805_bib143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc Receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2025.107805_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30523-6","article-title":"Zanubrutinib in B-cell malignancies","volume":"20","author":"Das","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2025.107805_bib145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107805_bib146","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib147","first-page":"531","article-title":"Zanubrutinib: a new BTK inhibitor for treatment of relapsed\/refractory mantle cell lymphoma","volume":"56","author":"Weaver","year":"2020"},{"key":"10.1016\/j.phrs.2025.107805_bib148","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor\u20051 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2025.107805_bib149","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.107805_bib150","first-page":"434","article-title":"LITFULOTM (ritlecitinib) capsules: A Janus Kinase 3 inhibitor for the treatment of severe alopecia areata","volume":"21","author":"Gupta","year":"2023","journal-title":"Skinmed"},{"key":"10.1016\/j.phrs.2025.107805_bib151","doi-asserted-by":"crossref","unstructured":"Telliez J.B., Dowty M.E., Wang L., Jussif J., Lin T., Li L., Moy E., Balbo P., Li W., Zhao Y., Crouse K., Dickinson C., Symanowicz P., Hegen M., Banker M.E., Vincent F., Unwalla R., Liang S., Gilbert A.M., Brown M.F., Hayward M., Montgomery J., Yang X., Bauman J., Trujillo J.I., Casimiro-Garcia A., Vajdos F.F., Leung L., Geoghegan K.F., Quazi A., Xuan D., Jones L., Hett E., Wright K., Clark J.D., Thorarensen A. Discovery of a JAK3-selective inhibitor: Functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol;11:3442\u20133451. doi: 10.1021\/acschembio.6b00677.","DOI":"10.1021\/acschembio.6b00677"},{"key":"10.1016\/j.phrs.2025.107805_bib152","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2025.107805_bib153","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107805_bib154","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.phrs.2018.10.021","article-title":"Pharmacological targeting of RAS: recent success with direct inhibitors","volume":"139","author":"O'Bryan","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107805_bib155","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.phrs.2025.107805_bib156","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2025.107805_bib157","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.jmedchem.6b00788","article-title":"Covalent modifiers: a chemical perspective on the reactivity of \u03b1,\u03b2-unsaturated carbonyls with thiols via hetero-Michael addition reactions","volume":"60","author":"Jackson","year":"2017","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib158","doi-asserted-by":"crossref","unstructured":"Baillie T.A. Targeted covalent inhibitors for drug design. Angew Chem Int Ed. 2016;55:13408313421. doi: 10.1002\/anie.201601091.","DOI":"10.1002\/anie.201601091"},{"key":"10.1016\/j.phrs.2025.107805_bib159","doi-asserted-by":"crossref","unstructured":"Gehringer M., Laufer S.A.. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem 2019;62:567335724. doi: 10.1021\/acs.jmedchem.8b01153.","DOI":"10.1021\/acs.jmedchem.8b01153"},{"key":"10.1016\/j.phrs.2025.107805_bib160","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib161","doi-asserted-by":"crossref","unstructured":"Baillie T.A.. Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opinion Drug Discov 2020;19:1313. doi: 10.1080\/17460441.2021.1832079.","DOI":"10.1080\/17460441.2021.1832079"},{"key":"10.1016\/j.phrs.2025.107805_bib162","doi-asserted-by":"crossref","unstructured":"Miseta A., Csutora P.. Relationship between the occurrence of cysteine in proteins and the complexity of organisms. Mol Biol Evol 2000;17:123231239. doi: 10.1093\/oxfordjournals.molbev.a026406.","DOI":"10.1093\/oxfordjournals.molbev.a026406"},{"key":"10.1016\/j.phrs.2025.107805_bib163","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.107805_bib164","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1021\/acs.jcim.4c00890","article-title":"Exploring extended warheads toward developing cysteine-targeted covalent kinase inhibitors","volume":"64","author":"Zhao","year":"2024","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.phrs.2025.107805_bib165","article-title":"Probing the protein kinases' cysteinome by covalent fragments","volume":"64","author":"Wang","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.phrs.2025.107805_bib166","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107805_bib167","doi-asserted-by":"crossref","unstructured":"Roskoski R. Jr. Guidelines for preparing color figures for everyone including the colorblind. Pharmacol Res. 2017119:240\u2013241. Erratum in: Pharmacol Res. 2019;139:569. doi: 10.1016\/j.phrs.2017.02.005.","DOI":"10.1016\/j.phrs.2018.09.019"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T23:19:19Z","timestamp":1764976759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":167,"alternative-id":["S1043661825002300"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107805","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107805"}}